Long noncoding RNA (lncRNA): a target in neuropathic pain

S Wu, J Bono, YX Tao - Expert opinion on therapeutic targets, 2019 - Taylor & Francis
S Wu, J Bono, YX Tao
Expert opinion on therapeutic targets, 2019Taylor & Francis
Introduction: Current treatments for neuropathic pain are limited in part due to the incomplete
understanding of its underlying mechanisms. Recent evidence reveals the dysregulated
expression of long non-coding RNAs (lncRNAs) in the damaged nerve, dorsal root ganglion
(DRG), and spinal cord dorsal horn following peripheral nerve injury. However, the role of
the majority of lncRNAs in neuropathic pain genesis is still elusive. Unveiling the
mechanisms of how lncRNAs participate in neuropathic pain may develop new strategies to …
Abstract
Introduction: Current treatments for neuropathic pain are limited in part due to the incomplete understanding of its underlying mechanisms. Recent evidence reveals the dysregulated expression of long non-coding RNAs (lncRNAs) in the damaged nerve, dorsal root ganglion (DRG), and spinal cord dorsal horn following peripheral nerve injury. However, the role of the majority of lncRNAs in neuropathic pain genesis is still elusive. Unveiling the mechanisms of how lncRNAs participate in neuropathic pain may develop new strategies to prevent and/or treat this disorder.
Areas covered: This review focuses on the dysregulation of lncRNAs in the DRG, dorsal horn, and the injured nerves from preclinical models of neuropathic pain. We provide evidence of how peripheral nerve injury causes the dysregulation of lncRNAs in these pain-related regions. The potential mechanisms of how dysregulated lncRNAs contribute to the pathogenesis of neuropathic pain are discussed.
Expert opinion: The investigation on the role of the dysregulated lncRNAs in neuropathic pain might open up a novel avenue for therapeutic treatment of this disorder. However, current investigation is at the infancy stage, which challenges the translation of preclinical findings. More intensive studies on lncRNAs are required before the preclinical findings are translated into therapeutic management for neuropathic pain.
Taylor & Francis Online